Discover how S. Karger has positioned itself as a reference in the healthcare industry by publishing trusted content for 30 years.
Novartis, Seagen veteran David Epstein is back, leading a new cancer startup
LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in